Selective small molecule inhibitors for hidradenitis suppurativa: Today and tomorrow
Authors:
- 1 December 2024
- journal article
- research article
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 91 (6) , S31-S36
Abstract
No abstract availableKeywords
This publication has 24 references indexed in Scilit:
- Efficacy and safety of the oral Janus kinase 1 inhibitor povorcitinib (INCB054707) in patients with hidradenitis suppurativa in a phase 2, randomized, double-blind, dose-ranging, placebo-controlled studyJournal of the American Academy of Dermatology, 2023
- 43799 Efficacy and Safety of Upadacitinib in Moderate-to-Severe Hidradenitis Suppurativa: A Phase 2, Randomized, Placebo-Controlled StudyJournal of the American Academy of Dermatology, 2023
- Emerging Treatments and the Clinical Trial Landscape for Hidradenitis Suppurativa Part I: Topical and Systemic Medical TherapiesDermatology and Therapy, 2023
- A proof-of-concept open-label clinical trial of spleen tyrosine kinase antagonism using fostamatinib in moderate-to-severe hidradenitis suppurativaJournal of the American Academy of Dermatology, 2023
- Small molecule inhibitors targeting the cancersMedcomm, 2022
- Sirolimus as combination rescue therapy with tumor necrosis alpha inhibitors for severe, refractory hidradenitis suppurativaJournal of the American Academy of Dermatology, 2020
- Apremilast for moderate hidradenitis suppurativa: Results of a randomized controlled trialJournal of the American Academy of Dermatology, 2019
- Activated mTORC1 signaling: The common driving force of type 2 diabetes and hidradenitis suppurativaJournal of the American Academy of Dermatology, 2018
- Apremilast in the treatment of moderate to severe hidradenitis suppurativa: A case series of 9 patientsJournal of the American Academy of Dermatology, 2017
- The JAK inhibitor tofacitinib regulates synovitis through inhibition of interferon‐γ and interleukin‐17 production by human CD4+ T cellsArthritis & Rheumatism, 2011